Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A Y788* ARID1A M1154fs |
Therapy | Bevacizumab + Pembrolizumab |
Indication/Tumor Type | ovarian clear cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A Y788* ARID1A M1154fs | ovarian clear cell carcinoma | predicted - sensitive | Bevacizumab + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with ovarian clear cell carcinoma harboring both ARID1A Y788* and M1154fs was sensitive to the combination therapy of Keytruda (pembrolizumab) and Avastin (bevacizumab), demonstrating a decrease in serum marker, tumor regression after 3 cycles, and complete remission after 9 cycles of treatment (PMID: 33292376). | 33292376 |
PubMed Id | Reference Title | Details |
---|---|---|
(33292376) | Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. | Full reference... |